ResMed/$RMD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ResMed
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Ticker
$RMD
Sector
Primary listing
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Employees
9,980
ISIN
US7611521078
Website
ResMed Metrics
BasicAdvanced
$37B
28.72
$8.91
0.76
$2.12
0.83%
Price and volume
Market cap
$37B
Beta
0.76
52-week high
$263.05
52-week low
$180.34
Average daily volume
837K
Dividend rate
$2.12
Financial strength
Current ratio
3.411
Quick ratio
1.957
Long term debt to equity
14.445
Total debt to equity
15.142
Dividend payout ratio (TTM)
23.14%
Interest coverage (TTM)
139.28%
Profitability
EBITDA (TTM)
1,763.114
Gross margin (TTM)
59.37%
Net profit margin (TTM)
26.15%
Operating margin (TTM)
32.10%
Effective tax rate (TTM)
16.74%
Revenue per employee (TTM)
$500,000
Management effectiveness
Return on assets (TTM)
14.01%
Return on equity (TTM)
25.81%
Valuation
Price to earnings (TTM)
28.722
Price to revenue (TTM)
7.483
Price to book
6.77
Price to tangible book (TTM)
16.55
Price to free cash flow (TTM)
24.09
Free cash flow yield (TTM)
4.15%
Free cash flow per share (TTM)
1,062.31%
Dividend yield (TTM)
0.83%
Forward dividend yield
0.83%
Growth
Revenue change (TTM)
9.54%
Earnings per share change (TTM)
37.08%
3-year revenue growth (CAGR)
12.37%
10-year revenue growth (CAGR)
11.83%
3-year earnings per share growth (CAGR)
18.91%
10-year earnings per share growth (CAGR)
13.69%
3-year dividend per share growth (CAGR)
7.21%
10-year dividend per share growth (CAGR)
6.62%
What the Analysts think about ResMed
Analyst ratings (Buy, Hold, Sell) for ResMed stock.
Bulls say / Bears say
ResMed reported a 9% year-over-year revenue growth in Q4 2024, reaching $1.2 billion, driven by strong demand for its sleep apnea devices. (reuters.com)
The company's gross margin improved by 350 basis points to 58.5% in Q4 2024, indicating enhanced operational efficiency. (stocktitan.net)
ResMed's SaaS business, including the Brightree ReSupply program, continues to demonstrate strong synergies, contributing to revenue growth in the Home Medical Equipment and Infusion segments. (nasdaq.com)
Analysts caution that the anticipated FDA approval of Eli Lilly's weight-loss drug, Zepbound, for sleep apnea by the end of 2024 could disrupt patient demand for ResMed's products. (reuters.com)
Global macroeconomic challenges, including supply chain disruptions and currency fluctuations, may adversely affect ResMed's operational results. (nasdaq.com)
The sleep-disordered breathing market is highly competitive, with major players like Philips and Fisher & Paykel Healthcare, potentially impacting ResMed's market share. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
ResMed Financial Performance
Revenues and expenses
ResMed Earnings Performance
Company profitability
ResMed News
AllArticlesVideos
Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025
GlobeNewsWire·1 month ago
Resmed Acquires VirtuOx
GlobeNewsWire·2 months ago
ResMed Boasts Double-Digit EPS Growth, Tariff Exemption: Analysts Boost Price Forecast
Benzinga·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ResMed stock?
ResMed (RMD) has a market cap of $37B as of June 25, 2025.
What is the P/E ratio for ResMed stock?
The price to earnings (P/E) ratio for ResMed (RMD) stock is 28.72 as of June 25, 2025.
Does ResMed stock pay dividends?
Yes, the ResMed (RMD) stock pays dividends to shareholders. As of June 25, 2025, the dividend rate is $2.12 and the yield is 0.83%. ResMed has a payout ratio of 23.14% on a trailing twelve-month basis.
When is the next ResMed dividend payment date?
The next ResMed (RMD) dividend payment date is unconfirmed.
What is the beta indicator for ResMed?
ResMed (RMD) has a beta rating of 0.76. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.